Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement
Corporate & Securities
WEXFORD, Pa., and MIAMI, Fla., April 19, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq: BHSE) (“Bull Horn”), a special purpose acquisition company (SPAC), today announced they have entered into a definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn. Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments).
Bridgeway Capital Partners and Meister Seelig & Schuster, PLLC served as financial and legal advisors, respectively, to Coeptis. Jones Trading and Ellenoff Grossman & Schole PLLC served as financial and legal advisors, respectively, to Bull Horn.
MSS’s Corporate Partner, Denis Dufresne acted as lead attorney on this merger agreement. To read the full press release, click here.
Attorneys Involved:
Recent Posts
